NCT03733470 is a Phase 4 clinical trial of Sildenafil study group in Emphysema, sponsored by Eric A. Hoffman.

Who is sponsoring NCT03733470?

NCT03733470 is sponsored by Eric A. Hoffman.

What drugs are being tested in NCT03733470?

Interventions in NCT03733470: Sildenafil study group.

Is NCT03733470 still recruiting?

NCT03733470 is currently completed. Last updated 1 October 2019.

Are results published for NCT03733470?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-10-01 · How we verify

NCT03733470

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypoxic Pulmonary Vasoconstriction Pilot Study

Completed Phase 4 Results posted Last updated 1 October 2019

What this trial tests

Phase 4 trial testing Sildenafil study group in Emphysema in 22 participants. Completed in 13 January 2014.

Timeline

29 June 2011

Primary endpoint
13 January 2014

13 January 2014

Quick facts

Lead sponsor	Eric A. Hoffman
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	22
Start date	29 June 2011
Primary completion	13 January 2014
Estimated completion	13 January 2014
Sites	1 location across United States

Drugs / interventions tested

Sildenafil study group — full drug profile →

Conditions studied

Emphysema — all drugs for Emphysema →

Sponsor

Eric A. Hoffman — full company profile →

Who can join

Adults 30 to 60, any sex, with Emphysema. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Perfused Blood Volume Assessed for a Change in Lung Inflammation Pre and Post Dose Sildenafil Administration Primary · Change of perfused blood volume from baseline at one hour after sildenafil administration.

Perfused blood volume will be measured by CT scan at two time points and compared at two points, pre and post the administration of sildenafil.

Group	Value	95% CI
Nonsusceptible Smokers (NS)	0.37	± 0.03
Susceptible Smoker (SS)	0.42	± 0.09

Sponsor's own description

The purpose of this study is to determine if the events leading to smoking-associated centrilobular and paraseptal emphysema are caused by a failure of the lungs' inherent mechanisms to block hypoxic pulmonary vasoconstriction (HPV) in areas of smoking-induced inflammation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Emphysema

Currently open trials in the same condition.

NCT07059637 — Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD · NA · recruiting
NCT06891755 — Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3 · NA · recruiting
NCT06025500 — Analysing Peripheral Skeletal Muscle Function Before and After Endobronchial Valve Treatment · recruiting
NCT06533371 — Clinical-ultrasonographic Assessment of Pulmonary Emphysema · NA · recruiting
NCT06528418 — Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath · recruiting

Other Eric A. Hoffman trials

Trials by the same sponsor.

NCT03382106 — Smoking Cessation and Functional CT Assessment · Phase 4 · completed
NCT03764163 — Image and Model Based Analysis of Lung Disease · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03733470 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eric A. Hoffman
Last refreshed: 1 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03733470.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing